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At present, the diagnosis of multiple sclerosis (MS) relies 
heavily on the use of MRI, which can demonstrate dis-
ease dissemination in space and time1–4. The current 
2010 McDonald criteria have enabled earlier diagno-
sis5,6 and initiation of disease-modifying treatment, with 
substantial benefits for disease outcome7,8, but they still 
have imperfect sensitivity and specificity9,10. The limited 
accuracy of the criteria results in challenging cases and 
misdiagnosis, which are prevalent problems in MS11,12. 
Therefore, more-accurate and pathologically specific 
MRI criteria are still needed to exclude other disorders 
that can mimic MS13,14.
The MRI-detectable central vein inside white mat-
ter lesions has recently been proposed as a biomarker 
of inflammatory demyelination and, thus, may aid the 
diagnosis of MS15. The ‘central vein sign’ (CVS) has been 
investigated in various neurological conditions by sev-
eral groups, and evidence has accumulated that the CVS 
may have the ability to accurately differentiate MS from 
its mimics15–21. As a consequence, recent guidelines from 
the Magnetic Resonance Imaging in MS (MAGNIMS) 
group1,4 and the Consortium of MS Centers (CMSC) 
task force22 have acknowledged the potential of the CVS 
and its dedicated MRI acquisitions for the differential 
diagnosis of MS, while calling for further research before 
considering a possible modification of the diagnostic 
criteria. However, the lack of standardization for the 
definition and imaging of the CVS, as well as a dearth 
of large-scale prospective studies evaluating the CVS 
for MS diagnosis, are currently preventing the clinical 
 validation of this potential biomarker1,23.
This Consensus Statement aims to provide recom-
mendations for the definition, standardization and 
clinical evaluation of the CVS in the diagnosis of MS. 
These statements are based on a thorough review of the 
existing literature on the CVS and the consensus opin-
ion of the members of the North American Imaging in 
Multiple Sclerosis (NAIMS) Cooperative (BOX 1).
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Abstract | Over the past few years, MRI has become an indispensable tool for diagnosing multiple 
sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and 
specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to 
improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS 
in individual lesions can accurately differentiate MS from other diseases that mimic this condition. 
However, the predictive value of the CVS for the development of clinical MS in patients with 
suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the 
definition and imaging of the CVS currently limits its clinical implementation and validation.  
On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of 
the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, this article 
provides statements and recommendations aimed at helping radiologists and neurologists to better 
understand, refine, standardize and evaluate the CVS in the diagnosis of MS.
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Methods
In November 2015, a panel of experts on the use of MRI 
in the management of MS convened at the University of 
Southern California, Los Angeles, USA. This meeting was 
organized by the NAIMS Cooperative — an independ-
ent network of clinical research groups that utilize MRI 
to better understand, diagnose and treat MS (BOX 1). The 
panel was composed of neurologists, neuro radiologists, 
MRI scientists, and statisticians from different NAIMS-
affiliated institutions in North America, as well as 
 international experts on the topic of CVS.
During the meeting, recently published literature on 
the CVS in neurological diseases, and associated MRI 
techniques, was discussed. The following five topics were 
addressed in detail: the central vein in MS; the central vein 
in other neurological diseases; radiological definition of 
the central vein and the CVS; imaging of central veins with 
MRI; and clinical evaluation of the CVS for MS diagno-
sis. After open discussion and debate, the group reached 
a consensus on statements and recommendations on each 
of these five topics. After the meeting, a draft of the Con-
sensus Statement was written by the first author on the 
basis of contributions from the panellists. This draft was 
then circulated to all NAIMS members, who modified the 
document until a final consensus agreement was reached.
The central vein in MS
Discussion
Central vessels (predominantly veins and venules) in 
MS plaques were reported by pathological studies as 
early as the 1820s24. The perivascular space surrounding 
these veins is thought to be a privileged site for immune 
cells to interact with antigen-presenting cells, which can 
then trigger an inflammatory cascade leading to the for-
mation of lesions around the veins25,26. With the devel-
opment of susceptibility-based magnetic resonance 
venography in the late 1990s27, it became possible to 
observe these central veins in MS plaques in vivo, as 
reported by Tan et al.28. This first in vivo demonstration 
of the perivenous distribution of MS plaques was fur-
ther confirmed in 2008 using ultra-high-field MRI29,30. 
Follow-up imaging studies confirmed this finding in 
relapsing–remitting MS (RRMS), secondary progressive 
MS (SPMS) and primary progressive MS (PPMS)31,32. 
This perivenous distribution in different MS subtypes 
is illustrated in FIG. 1.
In an imaging study, Kilsdonk et al. examined 1,004 
brain lesions in 33 patients with MS (19 with RRMS, 
nine with PPMS and five with SPMS), and found that 
78% of the lesions were located around a central vessel31. 
The proportion of total lesions with a central vein was 
not related to the clinical phenotype — a finding that 
was also supported by another study32. However, when 
lesions were classified according to their location, the 
authors reported that central veins were most prevalent 
in periventricular lesions (94%). This finding was con-
sistent across studies28,30, and might be explained by a 
higher density of parenchymal veins in peri ventricular 
regions. The proportion of CVS-positive lesions 
decreased with proximity to the neocortex (deep white 
matter lesions: 84%; juxtacortical lesions: 66%; mixed 
grey and white matter lesions: 52%; and intracortical 
lesions: 25%). However, a postmortem study has shown 
that the sites and characteristics of cortical lesions are 
strongly influenced by venous topography33 and, there-
fore, the association between cortical lesions and cen-
tral veins should be further investigated with dedicated 
imaging techniques.
Although most studies imaged the supratentorial 
brain only, central veins have also been demonstrated 
in lesions located in the thalamus, cerebellum and pons 
of patients with MS31,34. To our knowledge, no in vivo 
reports are available on central veins in MS lesions 
located in the spinal cord, although pathological evi-
dence of this phenomenon exists35. Another finding from 
the Kilsdonk et al. study was a significantly lower per-
centage of perivascular deep white matter lesions (73%) 
in MS patients aged ≥40 years compared with younger 
patients (92%). One possible explanation for this dis-
crepancy is the presence of age-related vascular lesions 
without central veins. This finding, which remains to be 
confirmed, supports the contribution of comorbidities to 
the brain lesion load in patients with MS36,37. To date, no 
imaging studies have been performed on the venocentric 
distribution of brain lesions in paediatric MS.
Statements and recommendations
• The presence of central veins inside MS lesions is a 
well-established finding in both ex vivo pathological 
studies and in vivo imaging studies
• The venocentric distribution of lesions exists in all 
MS clinical phenotypes (RRMS, SPMS and PPMS)
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• When imaging is used to examine the proportion 
of MS lesions with a central vein, the location of the 
lesion should be taken into account. Current evi dence 
suggests that the prevalence of central veins is highest 
in periventricular and deep white matter lesions
• The proportion of MS lesions with a central vein in 
the cortical, infratentorial and spinal cord regions 
remains underinvestigated, and additional imaging 
studies in these areas are recommended
• The effects of comorbidities (such as vascular con-
ditions) on the proportion of lesions with a central 
vein in patients with MS should not be neglected. 
Additional imaging studies on this issue would 
be useful
• The perivenous distribution of lesions in paediat-
ric MS has yet not been demonstrated, and future 
 imaging studies in this population are recommended
The central vein in other diseases
Discussion
Over the past few years, various research groups have 
used MRI to evaluate the presence of central veins inside 
white matter lesions associated with various neurological 
diseases, including neuromyelitis optica spectrum dis-
order (NMOSD), systemic autoimmune diseases (SAD), 
cerebral small vessel disease (CSVD), Susac syndrome, 
and migraine.
Neuromyelitis optica spectrum disorder. NMOSD is a 
CNS autoimmune disease that predominantly affects 
the optic nerves and spinal cord. NMOSD shares com-
mon radiological and clinical features with MS, and 
the differentiation between NMOSD and MS at early 
disease stages remains challenging. Sinnecker et al. 
reported that in ten patients with NMOSD who tested 
positive for aquaporin-4 autoantibodies (AQP4-IgG), 
only 35% of the 140 detected white matter lesions were 
located in the vicinity of — though rarely centred on 
— blood vessels19. In a different AQP4-IgG-seropositive 
NMOSD cohort (n = 10), Kister et al. reported that only 
eight of 92 lesions (9%) were traversed by a central ves-
sel17, further supporting the idea that vein-sensitive 
MRI could prove useful for differentiating NMOSD 
from MS. To date, no equivalent imaging studies have 
been performed in AQP4-IgG-seronegative negative 
patients with NMOSD.
Systemic autoimmune diseases. White matter lesions 
are commonly detected in SAD, especially when 
patients present with neurological symptoms. A recent 
pilot study38 recruited 38 patients: 24 with MS, and 14 
with SAD, including Behçet syndrome, systemic lupus 
erythematosus and antiphospholipid syndrome. The 
SAD group had a significantly lower percentage of 
lesions with central veins (median 15%, range 0–50%) 
than did the MS group (median 89%, range 68–100%). 
Patients with Behçet syndrome presented with the high-
est percentage of perivenous lesions (median 40%, range 
16–50%).
Cerebral small vessel disease. CSVD refers to patho-
logical changes in small brain vessels (small arteries, 
arterioles, capillaries and small veins) related to various 
aetiologies. CSVD is commonly associated with ageing, 
and is observed in populations with significant vascular 
risk factors. CSVD usually causes white matter lesions 
in the brain, which can mimic MS lesions. Although 
an early study by Lummel et al. reported no differences 
between patients with MS and CSVD in terms of the 
percentage of white matter lesions containing cen-
tral veins39, multiple recent studies have consistently 
reported a significantly lower proportion (45% at most) 
of venocentric white matter lesions in CSVD15,16,18,40,41 — 
a finding that is illustrated by a representative example 
in FIG. 1.
Susac syndrome. Susac syndrome is believed to be an 
autoimmune vasculopathy that causes occlusion of 
small vessels in the brain, retina and inner ear. A study 
of five patients with this very rare disease found that a 
Box 1 | The NAIMS Cooperative
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blood vessel was detectable in 54% of 148 white matter 
lesions21. Interestingly, the identified blood vessels were 
most commonly located at the lesion periphery.
Migraine. Radiographic findings in migraine can be 
mistaken for MS. A recent study found that the per-
centage of lesions with a central vein was significantly 
lower in migraine than in MS, with a median percentage 
of 22 (quartiles: 15, 54) in a cohort of ten patients with 
migraine20. This finding is illustrated by a representative 
example in FIG. 1.
Other diseases. The presence of central veins within white 
matter lesions in disorders with highly overlapping patho-
logical findings to MS, such as acute disseminated enceph-
alomyelitis (ADEM)42,43, has not yet been investigated.
Statements and recommendations
• The available evidence from MRI studies indicates 
that in comparison to patients with MS, individu-
als with AQP4-IgG-positive NMOSD, SAD (Behçet 
syndrome, systemic lupus erythematosus and anti-
phospholipid syndrome), CSVD, Susac syndrome 
and migraine have a significantly lower proportion of 
brain lesions with a central vein. These early results 
need to be validated by future studies. Other MRI 
mimics of MS, such as neurosarcoidosis and Sjögren 
syndrome13, should also be investigated
• Pathological mimics of MS, such as ADEM, require 
further investigation to assess the presence of the 
 central veins on MRI
• Because the differential diagnosis of MS is broad, 
pooling of data from multiple centres would be 
Nature Reviews | Neurology
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Axial
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Figure 1 | Perivenous distribution of multiple sclerosis lesions. 3 T FLAIR* (combined T2*-weighted MRI and 
fluid-attenuated inversion recovery) images from four individuals with a variety of neurological conditions, who were 
scanned at different sites. In the patients with relapsing–remitting or primary progressive multiple sclerosis (MS), a 
central vessel is visible in most hyperintense lesions (data from the NIH cohort). The dark veins are located centrally in 
the lesion and can be visualized in at least two perpendicular planes (arrows in magnified boxes). On the other hand,  
a central vein is absent from most of the lesions (arrowheads in magnified boxes) in the patient with migraine 
(University of Vermont cohort) and the patient with ischaemic small vessel disease (University of Nottingham cohort).
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a realistic strategy to perform a systematic, well- 
powered evaluation of the central vein in a variety 
of diseases
Radiological definitions
Discussion
An accepted standard radiological definition of the 
central vein would be useful to enable uniform imaging 
practices among clinicians. Interestingly, existing studies 
demonstrate good agreement when defining the radio-
logical characteristics of a central vein15–17,20,28,30–32,38,44–47: 
first, the vein should appear as a thin line or dot; second, 
when technically possible, the vein should be visualized 
in at least two perpendicular planes; and third, the vein 
can run partially or entirely through the lesion, but 
must be located centrally regardless of the lesion’s shape. 
In BOX 2, we suggest a standard radiological definition 
based on these characteristics. Examples of lesions with 
and without central veins are provided in FIGS 1,2.
A more challenging task is to establish a standard 
radiological definition of the CVS to improve diagno-
sis of MS. One proposed definition is the ‘40% rule’, 
first introduced by Evangelou and colleagues15, which 
assesses the percentage of lesions with a central vein 
and uses a cut-off value of 40% to radiologically dis-
tinguish MS from non-MS disease states. This simple 
threshold approach was successfully confirmed (100% 
positive and negative predictive value for MS) by the 
same group in a prospective study involving 29 patients 
who presented with possible MS, that is, typical clinically 
isolated syndrome (CIS) with insufficient MRI findings, 
or an atypical CIS presentation with MRI findings sug-
gestive of MS46. The 40% rule was further confirmed by 
an indepen dent group in a cohort of 17 patients with 
RRMS44. A recent study, in which patients with MS were 
compared with healthy volunteers and non-MS patients 
presenting with neurological syndromes, confirmed that 
diagnostic certainty could be increased by combining the 
published MRI criteria with visual assessment of the 40% 
rule48. However, this rule has some limitations, as count-
ing the number of lesions would be time- consuming in 
patients with high lesion load and, as highlighted above, 
>40% of brain lesions can be CVS-positive in some 
patients without MS.
Another approach, first tested by Kilsdonk et al., 
combines the number and location of lesions with the 
percentage of lesions with a central vein16. In a cohort 
of 16 patients with MS and 16 individuals with risk fac-
tors for vascular disease, the authors reported that MS 
could be diagnosed with a sensitivity of 100% (95% CI 
83–100%) and a specificity of 88% (95% CI 62–98%) 
when all lesions in the brain were considered. When 
the analysis was restricted to deep white matter lesions, 
the authors still found a relatively high sensitivity of 
81% (95% CI 54–96%), and the specificity increased 
to 94% (95% CI 70–100%). The capacity of the central 
vein to discriminate between MS and non-MS white 
matter lesions was confirmed in another study with five 
MS and nine non-MS patients, which reported a sensi-
tivity of 84%, a specificity of 89%, a positive predictive 
value of 94%, a negative predictive value of 73%, and a 
diagnostic accuracy of 86%45. However, this approach 
still requires the total number of lesions to be counted 
in patients’ brains.
To overcome this issue, one group recently proposed 
that assessment of ten lesions per patient might be suf-
ficient. By use of this approach, a diagnosis of MS could 
be predicted with 90% accuracy in 44 of 45 patients15. 
More recently, an even simpler set of diagnostic rules 
for CVS was introduced, consisting of the following 
three criteria18: if there are six or more morphologically 
characteristic lesions, the diagnosis is inflammatory 
demyelination; if there are fewer than six morpholog-
ically characteristic lesions, but morphologically char-
acteristic lesions outnumber non-perivenous lesions, 
the diagnosis is inflammatory demyelination; if neither 
of these conditions are met, inflammatory demyelina-
tion should not be diagnosed. The morphologically 
characteristic lesions considered here had a ‘coffee 
bean’ or ‘Dawson’s finger’ appearance when the MRI 
slice was along the vein’s axis, and a ‘ring’ or ‘dough-
nut’ appearance when the MRI slice was approximately 
perpendicular to the vein. By applying these rules in a 
cohort of 13 patients with MS and seven patients diag-
nosed with small vessel ischaemia, all patients were 
correctly classified, and the classification process took 
<2 min per case.
Standardized lesion selection, based on existing MRI 
criteria2,3,49,50, would enable the proposed CVS rules to 
be compared across different raters and sites. Given 
the potential confounding factors of small perivascular 
spaces surrounding veins (Virchow–Robin space), con-
fluent lesions, lesions with multiple distinct veins, and 
lesions that are poorly visible owing to image artefacts, 
we introduce a set of exclusion criteria for lesions (BOX 2). 
Examples of excluded lesions are provided in FIG. 2.
Statements and recommendations
• A standard radiological definition of a central vein 
should rely on the characteristics outlined in BOX 2
Box 2 | Radiological definition of a central vein
A central vein exhibits the following properties on 
T2*‑weighted images:
• Appears as a thin hypointense line or small 
hypointense dot
• Can be visualized in at least two perpendicular MRI 
planes, and appears as a thin line in at least one plane
• Has a small apparent diameter (<2 mm)
• Runs partially or entirely through the lesion
• Is positioned centrally in the lesion (that is, located 
approximately equidistant from the lesion’s edges and 
passing through the edge at no more than two places), 
regardless of the lesion’s shape
Exclusion criteria for lesions:
• Lesion is <3 mm in diameter in any plane
• Lesion merges with another lesion (confluent lesions)
• Lesion has multiple distinct veins
• Lesion is poorly visible (owing to motion or other 
MRI‑related artefacts)
C O N S E N S U S  S TAT E M E N T
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• No standard radiological definition of the CVS has 
yet been established
• To define the CVS, we need a set of simple rules that 
are practical for clinicians to use while providing the 
highest possible accuracy and confidence
• Because patients without MS can display a central 
vein in >40% of their total lesions, the proposed ‘40% 
rule’ might not be applicable for all diseases
• When defining the CVS, several exclusion criteria 
should be applied to lesions (BOX 2)
Imaging central veins with MRI
Discussion
Structural imaging of small cerebral veins is best 
done using the T2*-based contrast mechanism, 
which exploits the magnetic properties of blood27. 
The paramagnetic deoxyhaemoglobin inside venous 
blood perturbs the local magnetic field and generates 
reduced signal intensity in voxels containing a vein, 
causing veins to appear hypointense on T2*-weighted 
images27,51. Since the first in vivo observation of central 
veins in the brains of patients with MS28, a variety of 
T2*-based acquisitions have been employed at differ-
ent magnetic field strengths to image veins inside MS 
plaques30,34,45,46,52,53.
Several studies have employed a conventional 2D 
gradient-echo (GRE) sequence, which allows exqui-
site submillimetre in-plane resolution, especially at 7 T 
(REFS 17,19,21,29,32,52). However, 2D GRE acquisitions 
are typically slow (>10 min), only partially cover the 
supratentorial brain, and provide poor image resolution 
in the inferior–superior plane owing to thick slices and/or 
slice gaps.
Some studies have utilized a 3D T2*-weighted 
GRE sequence to overcome the slice gap issue, and 
have applied parallel imaging to shorten scan time 
while maintaining high image resolution (typically 
0.5 × 0.5 × 1–3 mm)39,45,54,55. These T2*-weighted images 
can be post-processed using the susceptibility-weighted 
imaging (SWI) technique to further enhance venous 
conspicuity56. The 3D GRE sequence can also be set 
up to have a multi-echo read-out57. The multi-echo 
acquisition can then provide quantitative (and/or 
multi-contrast) imaging through the use of advanced 
post-processing techniques58,59.
Another variation of the 3D GRE sequence uses a seg-
mented echo planar imaging (3D EPI) read-out to speed 
up the acquisition while providing more-efficient brain 
coverage and isotropic voxel size60. Isotropic resolution 
— a feature that is available on many radiology viewing 
platforms — is particularly useful to reformat images in 
any desired plane, and enables veins to be well visual-
ized irrespective of their orientation. Moreover, the use 
of small isotropic voxel dimensions increases the sensi-
tivity to small parenchymal veins within lesions61, while 
reducing the sensitivity to artefacts due to background 
field inhomogeneities. A shorter scan is also beneficial 
for limiting the head motion that can occur during the 
acquisition. Recently, the 3D EPI approach was dem-
onstrated to image perivenous MS lesions throughout 
Figure 2 | Examples of lesions with and without central veins. The lesions are classified as harbouring a central vein 
(parts a–c), not harbouring a central vein (parts d–f), or excluded from analysis (parts g–i). FLAIR* (combined T2*-weighted 
MRI and fluid-attenuated inversion recovery) images were collected at 3 T from the NIH multiple sclerosis cohort, and 
were reformatted in all three planes (axial, coronal and sagittal). The relevant lesions are indicated by arrowheads in each 
case. a | Dawson’s finger-shaped lesion with a central vein running perpendicular to the sagittal plane. b | Periventricular 
lesion with a hypointense rim located next to the atrium of the lateral ventricle. c | Small finger-like lesion with a diameter 
slightly >3 mm in its short axis. The central vein is not as conspicuous as in previous examples, but it is still visible. d | Small 
deep white matter lesion with diameter >3 mm and no visible central vein in any plane. e | Small subcortical lesion with 
diameter >3 mm and no visible central vein in any plane. f | Juxtacortical lesion with no visible central vein in any plane. 
g | Small hyperintense area with diameter <3 mm located around a parenchymal vein. h | Periventricular lesion with 
branching veins. i | Confluent lesions with multiple veins.
Nature Reviews | Neurology
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the brain at submillimetre resolution (0.55 mm iso-
tropic) in <4 min using a 3 T MRI scanner53. Moreover, 
this 3D EPI acquisition was shown to be more sensitive 
than conventional 3D T2* GRE41, probably owing to its 
smaller voxel dimensions.
Although T2*-based imaging with a 7 T scanner pro-
vides the highest sensitivity for central vein detection47, 
1.5 T (REF. 38) and 3 T (REF. 61) scanners can still provide 
high rates (>80%) of vein detection if optimized T2* 
protocols are used. Another way to increase vein con-
spicuity on T2*-weighted images is to perform SWI28,62 
and/or inject an intravascular contrast agent (a chelate 
of gadolinium, which is paramagnetic) during the MRI 
acquisition28,53,63. The latter solution is straightforward 
to implement, as MRI protocols for MS often involve 
the injection of contrast agent, which can be accom-
plished via a power injector while the scan is ongoing. 
Compared with manual contrast injection by a tech-
nician and the recommended 5 min wait before post- 
contrast imaging4,22, such a procedure would not prolong 
the MRI examination.
Unlike T2-weighted fluid-attenuated inversion 
recovery (FLAIR) images, T2*-weighted and SWI 
images lack cerebrospinal fluid suppression and are, 
therefore, less able to demonstrate contrast between 
lesions and surrounding tissues, making the detection 
of lesions more difficult. To overcome these issues, two 
research groups have recently proposed that FLAIR and 
T2* images should be combined in a single image34,55. 
Grabner et al.55 introduced a method that transforms 
FLAIR images using SWI phase masks from T2*-
weighted images, thereby creating a FLAIR–SWI con-
trast. The other approach, proposed by Sati et al.34 and 
known as FLAIR*, uses 1 mm isotropic 3D FLAIR 
(for lesion detection) and 0.55 mm isotropic 3D EPI (for 
vein detection) sequences — both acquired in <10 min 
— and provides high-resolution isotropic images of the 
whole brain. Recent studies reported on the utility of 
FLAIR* at various field strengths for differentiating MS 
from other diseases16,20,64, and for improving diagnostic 
accuracy31,44,48.
T2*-based imaging of the spinal cord is much more 
challenging, owing to factors such as the small physical 
dimensions of the spinal cord, strong magnetic field 
inhomogeneity caused by surrounding tissues (bones, 
soft tissues and air), and physiological motion (pulsa-
tion of cerebrospinal fluid flow, and cardiac and res-
piratory movement). Nonetheless, recent studies have 
demonstrated that high-quality, high-resolution T2*-
weighted imaging of the cervical65,66 and thoracic67 cord 
is possible in patients with MS. However, no central vein 
findings have yet been reported.
Standardization of the optimized MRI acquisitions 
across centres will be important for the widespread 
dissemination of central vein imaging. Similarly, 
standardized image reading and interpretation guide-
lines will be required to train radiologists and neuro-
radiologists from non-specialist centres. This process 
could, in principle, be facilitated by future development 
of automated image analysis tools for the detection of 
central veins.
Statements and recommendations
• Imaging of veins in the brain can be performed using 
T2*-based MRI sequences at any magnetic field 
strength (1.5 T, 3 T or 7 T). Although T2* imaging is 
most sensitive at 7 T, a high detection rate can still be 
achieved at clinical field strengths (1.5 T and 3 T) with 
optimized sequences
• Owing to the small dimensions of the central veins, 
images should be acquired at the highest resolution 
possible. The use of submillimetre voxel dimensions 
can be particularly helpful
• Images should be acquired using isotropic voxels 
to enable multiplanar visualization of central veins 
regardless of their orientation in the brain
• Specific acquisition protocols (with SWI and/or 
gado linium injection) aimed at improving central 
vein detection require further evaluation, especially 
at lower field strength (1.5 T)
• High-resolution isotropic T2*with 3D EPI is cur-
rently the most promising acquisition to adequately 
detect central veins while preserving a clinically com-
patible scan time. However, its use will be limited to 
expert academic centres until the sequence is made 
routinely available by MRI scanner manufacturers
• Combined FLAIR and T2* images have the poten-
tial to become a standard clinical protocol, but 
 manufacturer-provided software for direct, automatic 
image post-processing on the scanner is necessary for 
widespread dissemination
• The intra-rater, inter-rater, scan–rescan and inter- 
scanner reliability of central vein detection on the 
optimized MRI sequences should be investigated
• High-quality, high-resolution T2*-weighted imaging 
of the spinal cord to detect central veins in MS lesions 
needs further development
Evaluating the CVS for MS diagnosis
Discussion
Most studies on the use of the CVS for MS diagnosis 
have included small cohorts of patients in whom the 
diagnosis (MS or one of its mimics) was already known. 
As discussed above, the results from these single-centre 
studies support a beneficial role for the CVS in spe-
cifically identifying MS lesions. However, larger-scale 
studies are still required to confirm these early results.
To formally establish the clinical value of the CVS 
for the differential diagnosis at disease onset, a large, 
prospective, multicentre study including patients at first 
presentation of possible MS is necessary. In any study 
design, important factors such as disease duration, dis-
ease severity and lesion load would need to be taken into 
account, as they might affect the frequency of the central 
vein in MS mimics. For example, larger lesions are more 
likely to incidentally harbour a blood vessel, although 
the vessel location in lesions caused by MS mimics is 
more likely to be eccentric than central.
Although differential diagnosis is the most obvious 
diagnostic application of the CVS, one study has pro-
spectively investigated the predictive diagnostic value of 
the CVS in patients in whom the question of inflamma-
tory demyelination had been raised at first presentation, 
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that is, patients showing typical CIS or with atypical 
neuro logical presentations46. In this longitudinal study, 
29 undiagnosed individuals were recruited and under-
went a T2*-weighted scan. On the basis of the CVS only, 
a provisional diagnosis of MS was predicted using the 
40% rule. Of the 22 patients who eventually received a 
clinical diagnosis within a median follow-up period of 
26 months, 13 patients diagnosed as having MS had cen-
tral veins in >40% of brain lesions at baseline. All nine 
patients whose condition was not diagnosed as MS had 
central veins in <40% of lesions. According to these data, 
the CVS had 100% positive and negative predictive value 
for the diagnosis of MS, although the conclusions were 
limited by the small number of participants.
To further validate these early results, the same 
group is currently conducting a prospective longitudi-
nal clinical trial68 aiming to recruit 60 patients suspected 
— but not proven — to have MS. Recruited patients will 
undergo a single research MRI brain scan at 3 T, which 
will be evaluated by blinded investigators to make a 
diagnosis of MS or non-MS on the basis of the CVS cri-
terion only. No other research tests will be performed, 
and the patients will be followed up over time until a 
final diagnosis is made. Although this prospective study 
should provide strong evidence to support or refute the 
predictive value of the CVS for MS diagnosis, it remains 
a single-centre trial and is, therefore, limited in terms of 
cohort size and external validity. The clinical validation 
would benefit from a multicentre trial using a similar 
design but including a larger number of participants 
and centres, as well as standardized MRI protocols and 
methodology for CVS identification.
An alternative study design could be used to inves-
tigate whether the CVS improves the accuracy of the 
2010 McDonald criteria. Modifications of existing 
MRI criteria to incorporate the CVS could be tested 
initially in a single-centre prospective study recruiting 
patients with CIS (or even with radiologically isolated 
syndrome), followed by a larger-scale multicentre study 
if the preliminary results are positive.
Statements and recommendations
• The clinical value of the CVS should be evaluated in 
the context of the differential diagnosis of suspected 
MS, the diagnostic predictive value in patients with 
possible or early MS, and the potentially improved 
accuracy of the 2010 McDonald criteria
• Currently available evidence from a small prospective 
study supports the high predictive value of the CVS 
in the diagnosis of MS in patients with typical CIS or 
atypical neurological presentations
• Large, prospective multicentre trials including 
patients at first presentation of neurological signs are 
needed to evaluate the clinical value of the CVS for 
MS diagnosis
• Care should be taken when using the CVS in routine 
clinical practice until its diagnostic value has been 
formally established
Conclusions
The NAIMS Cooperative has developed this Consensus 
Statement to better define and evaluate the CVS, as 
detected by MRI, for the diagnosis of MS. More precisely, 
our recommendations underscore the need for further 
investigation of the central vein in MS and its mimics. 
We have proposed a standard radiological definition 
of the central vein (BOX 2), but we strongly recommend 
additional investigation to define the optimal CVS cri-
teria. Our recommendations also promote standardi-
zation of MRI protocols and lesion selection criteria to 
assess central veins. Finally, we recommend investigation 
of the clinical value of the CVS through large multi centre 
studies involving patients with established diagnoses 
of MS and its mimics, as well as undiagnosed patients 
 suspected of having MS.
Taken together, our recommendations provide a 
roadmap to help establish a high-impact role for the 
CVS in improving the diagnosis of MS. This Consensus 
Statement is in line with recent guidelines from the 
MAGNIMS group1,4 and CMSC task force22, which 
both highlighted the potential of the CVS and its associ-
ated MRI acquisitions while calling for further research 
before considering an update of the diagnostic criteria. 
Overall, the NAIMS Cooperative is optimistic that the 
CVS will eventually find substantial clinical utility in 
daily practice, thus adding another layer of success to a 
technology that has changed the field of neurology over 
the past few decades.
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